title: Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease.
abstract: Dopamine receptor agonists and L-dihydroxyphenylalanine (L-DOPA) counteract dopamine loss in the striatum and are therefore used in the treatment of Parkinson's disease (PD). T-Lymphocytes express some features of the dopaminergic system, and their function or activation might be regulated by dopaminergic treatments. Two-dimensional electrophoresis of total protein extract from T-lymphocytes was performed to identify therapy-induced proteome changes in T-cells of 17 patients with PD. Specific protein level alterations were further validated by Western blotting. Of 17 enrolled patients, 11 were treated with different doses of L-DOPA; in this group, we found that the levels of two spots, corresponding to ATP synthase subunit β and proteasome subunit β type-2, correlated linearly with the L-DOPA daily dose. Moreover, we identified seven proteins (prolidase, actin-related protein 2, F-actin-capping protein subunit β, tropomyosin α-3 chain, proteasome activator complex subunit 1, peroxiredoxin 6, and a glyceraldehyde-3-phosphate dehydrogenase isoform) whose levels were significantly different in patients treated with dopamine agonists. These findings demonstrate that dopaminergic stimulation has important effects on T-cell proteome in patients under long-term treatment. Therefore, therapies acting on the dopaminergic system may have additional effects on the immune system.
authors: Department of Theoretical and Applied Sciences, Division of Biomedical Sciences, and Centre of Neuroscience, University of Insubria, Busto Arsizio (VA), Italy. tiziana.alberio@uninsubria.it
authors: Tiziana
authors: T
authors: Alberio
authors: Agnese C
authors: AC
authors: Pippione
authors: Cristoforo
authors: C
authors: Comi
authors: Simone
authors: S
authors: Olgiati
authors: Daniela
authors: D
authors: Cecconi
authors: Maurizio
authors: M
authors: Zibetti
authors: Leonardo
authors: L
authors: Lopiano
authors: Mauro
authors: M
authors: Fasano
mesh_terms: D000328:Adult; D000368:Aged; D015153:Blotting, Western; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000008:administration & dosage*; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D025261:Mitochondrial Proton-Translocating ATPases / Q000235:genetics / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D046988:Proteasome Endopeptidase Complex / Q000235:genetics / Q000378:metabolism; D020543:Proteome / Q000235:genetics* / Q000378:metabolism; D040901:Proteomics; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology
chemical_list: C506526:ATP5F1B protein, human; D018491:Dopamine Agonists; D020543:Proteome; D007980:Levodopa; C561469:PSMB2 protein, human; D046988:Proteasome Endopeptidase Complex; D025261:Mitochondrial Proton-Translocating ATPases; D004298:Dopamine